Author at Microdose

Alp Ergin

Previously worked in Life Sciences Equity Research at Hannam and Partners, supporting a wide range of clients in the emerging psychedelic industry. Co-authored numerous research reports, including "flash", "initiating coverage" and industry pieces analysing the therapeutic and investment potential of psychedelics. Alp is currently an investment analyst for Negev Capital.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Finance

16 May 2023

Q1 Psychedelics Report: Reform, Research, and Raises

As we move into the 2nd quarter of 2023, we take a look at Q1 and other trends in the psychedelic medicine sector...

By Alp Ergin

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Follow us on social

Latest News

You Might Also Like

9 Feb 2026

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

For much of the last decade, psychedelic medicine has been driven by clinical outcomes first and mechanistic explanations second. Promising results in depression, anxiety, and trauma propelled compounds like psilocybin...

By Madison Roberts

19 Jan 2026

Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative

An industry wide look at how neuroplastogens are reshaping psychedelic medicine in 2026, with insights on Delix, AbbVie’s Gilgamesh acquisition, Enveric, and the shift toward nonhallucinogenic brain therapeutics....

By Madison Roberts

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

Previously worked in Life Sciences Equity Research at Hannam and Partners, supporting a wide range of clients in the emerging psychedelic industry. Co-authored numerous research reports, including "flash", "initiating coverage" and industry pieces analysing the therapeutic and investment potential of psychedelics. Alp is currently an investment analyst for Negev Capital.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Follow us on social

WordPress Ads